Qualigen Therapeutics (NASDAQ:AIXC) Stock Price Down 0.7% – Time to Sell?

Qualigen Therapeutics, Inc. (NASDAQ:AIXC)’s share price was down 0.7% during trading on Monday . The stock traded as low as $1.3150 and last traded at $1.35. Approximately 25,224 shares changed hands during trading, a decline of 57% from the average daily volume of 58,966 shares. The stock had previously closed at $1.36.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings started coverage on Qualigen Therapeutics in a research note on Monday, January 26th. They set a “sell (e+)” rating on the stock. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Qualigen Therapeutics Stock Performance

The stock has a market cap of $27.32 million, a PE ratio of -0.18 and a beta of 0.31. The company’s 50 day simple moving average is $1.25.

Qualigen Therapeutics (NASDAQ:AIXC) last posted its earnings results on Monday, March 30th. The company reported ($3.76) earnings per share (EPS) for the quarter.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.